Tidak mengudara

Berita berkelanjutan · 1 laporan

Trump administration's ibogaine fast-track effort

Pertama tayang Terbaru tayang

Sedang berkembangPemeriksaan berikutnya : Whether the administration or FDA abandons the effort, or the FDA completes a decision on ibogaine’s development or approval pathway.

Perkembangan terkini

As of July 23, 2026, the Trump administration was pushing to fast-track ibogaine for addiction treatment, while experts cited cardiac risks linked to potentially fatal arrhythmias. The report identifies Trump and the FDA as decision-makers but gives no decision, next step or indication that the effort has been abandoned.

Pelacak beritaHari ke-1

1 laporan11 media11 sumber1 video

Perkembangan sejauh ini

  1. Pembaruan ke-1

    Twenty-Seven Dead, No FDA Approval, and a Presidential Pen

    Trump's April executive order fast-tracks ibogaine, a Schedule I psychedelic with documented cardiac risk, while Americans keep dying at unregulated clinics abroad.

    Masih terbuka setelah laporan ini

    • The full death toll at foreign clinics, including non-American patients, is not publicly tracked.
    • How the FDA will interpret "expedite" — whether it fast-tracks a specific application or reopens the research pathway — has not been disclosed.
    • Whether Texas's state-funded trials will produce randomized data sufficient for an FDA submission.

Riwayat

  1. Dibuka1 laporan

Siapa yang terlibat

Tokoh

  • Céline GounderAmerican infectious disease physician, internist, epidemiologist, filmmaker, and medical journalist1 laporan
  • Donald TrumpPresident of the United States (2017–2021; since 2025)1 laporan
  • Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 laporan

Tempat

  • MexicoMexico1 laporan
  • Stanford University450 Jane Stanford Way, Stanford, CA 94305, USA1 laporan
  • TexasTexas, USA1 laporan
  • The Oval Office1600 Pennsylvania Ave NW, Washington, DC 20500, USA1 laporan

Semua media yang kami baca tentang berita ini

11 sumber11 media1 video